Your browser doesn't support javascript.
loading
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial.
Ramos, Pedro Marques; Choi, Jeea; Campbell, Catarina D; Wang, Ying A; Pallaud, Celine; Dickinson, Michael; Verma, Amit; Mittelman, Moshe; Platzbecker, Uwe; Cherif, Honar; Fenaux, Pierre.
Afiliación
  • Ramos PM; Novartis Pharma AG Basel Switzerland.
  • Choi J; Novartis Pharmaceuticals Corporation East Hanover New Jersey USA.
  • Campbell CD; Novartis Institutes of BioMedical Research Cambridge Massachusetts USA.
  • Wang YA; Novartis Global Drug Development Cambridge Massachusetts USA.
  • Pallaud C; Present address: Bayer Pharmaceuticals Corporation Cambridge MA USA.
  • Dickinson M; Present address: Bayer Pharmaceuticals Corporation Cambridge MA USA.
  • Verma A; Novartis Pharma AG Basel Switzerland.
  • Mittelman M; The Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne Australia.
  • Platzbecker U; Division of Medical Oncology Department of Medicine Albert Einstein College of Medicine New York New York USA.
  • Cherif H; Tel Aviv Sourasky Medical Center Tel Aviv University Tel Aviv Israel.
  • Fenaux P; Medical Clinical and Policlinic Hematology and Cellular Therapy University Hospital Leipzig Leipzig Germany.
EJHaem ; 4(3): 876-881, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37601870
Eltrombopag has been previously shown to be effective in reversing azacitidine-mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with intermediate- to high-risk myelodysplastic syndromes and thrombocytopenia. The results did not support a clinical benefit for the addition of eltrombopag to azacitidine. We investigated if the somatic mutational profiles in the patient cohort were associated with treatment outcomes. Based on the available data, we observed no imbalance in the mutational profiles between treatment arms or a clear association between identified somatic mutations and clinical outcomes.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos